Literature DB >> 18456765

Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

A Horwich1, C Parker, V Kataja.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18456765     DOI： 10.1093/annonc/mdn084

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Histrelin: in advanced prostate cancer.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 2.  Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review.

Authors:  Saskia Van der Meer; Sabine A M Löwik; Willem H Hirdes; Rien M Nijman; Klaas Van der Meer; Josette E H M Hoekstra-Weebers; Marco H Blanker
Journal:  BMC Fam Pract       Date:  2012-10-11       Impact factor: 2.497

3.  Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.

Authors:  E David Crawford; Jason M Phillips
Journal:  Cancer Manag Res       Date:  2011-07-20       Impact factor: 3.989

Review 4.  Triptorelin embonate (6-month formulation).

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2010-02-12       Impact factor: 11.431
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.